TD2 Immuno-Oncology

Executive Interview with TD2

TD2 Clinical Capabilities

Partner with an Experienced, Scientifically-Driven Cncology CRO

Cell Therapy at TD2

Tech Slam


Tech Slam

Clinical Trial Highlight

CAR-T Summit Tech Slam

Glioblastoma Capabilities

Biomarkers and the utility of proteomics for dose optimization and confirmation of target engagement

The Dynamic Trial Design

Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response

Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers

Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…

Exploring the Effects of Microbiome in Precision Oncology Therapeutic Development

Improving Cancer Trial Recruitment With Advanced Analytics and Prospective Data

Data Insights: Identifying Early Signs of Safety and Efficacy in Oncology Clinical Trials

The Dynamic Trial: Is It the Right Option for You?

Efficient Data Management: One Way to Expedite the Clinical Development Process

Many Drugs Don’t Move Past Phase I. Will Yours?


Get free tips, tools and resources by subscribing to the TD2 newsletter.